These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10485736)

  • 1. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation.
    Kleinert S
    Lancet; 1999 Sep; 354(9181):841. PubMed ID: 10485736
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
    Sica DA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):597-601. PubMed ID: 11496052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.
    Chaturvedi N
    Lancet; 2000 Jan; 355(9200):246-7. PubMed ID: 10675066
    [No Abstract]   [Full Text] [Related]  

  • 5. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.
    Tu K; Mamdani MM; Jacka RM; Forde NJ; Rothwell DM; Tu JV
    CMAJ; 2003 Mar; 168(5):553-7. PubMed ID: 12615747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
    Pocanić D
    Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
    Scheen AJ
    Rev Med Liege; 1999 Oct; 54(10):835-6. PubMed ID: 10605322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
    Carroll CA; Coen MM; Rymer MM
    Clin Ther; 2003 Apr; 25(4):1248-61. PubMed ID: 12809971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
    Hoogwerf BJ; Young JB
    Cleve Clin J Med; 2000 Apr; 67(4):287-93. PubMed ID: 10780101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.
    Lewis V; Kloer P; Prasad N; Alcolado JC
    Lancet; 2000 Apr; 355(9210):1182; author reply 1183-4. PubMed ID: 10791399
    [No Abstract]   [Full Text] [Related]  

  • 14. HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation.
    Donnelly R
    Diabetes Obes Metab; 2000 Jan; 2(1):1-2. PubMed ID: 11220348
    [No Abstract]   [Full Text] [Related]  

  • 15. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.
    Fegan G; Ward D; Clarke L; MacLeod K; Hattersley A
    Lancet; 2000 Apr; 355(9210):1182-3; author reply 1183-4. PubMed ID: 10791400
    [No Abstract]   [Full Text] [Related]  

  • 16. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
    Lièvre M; Marre M; Chatellier G; Plouin P; Réglier J; Richardson L; Bugnard F; Vasmant D
    Control Clin Trials; 2000 Aug; 21(4):383-96. PubMed ID: 10913814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.
    Marshall SM
    Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826
    [No Abstract]   [Full Text] [Related]  

  • 18. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.
    Webster MW
    Lancet; 2000 Apr; 355(9210):1181-2; author reply 1183-4. PubMed ID: 10791398
    [No Abstract]   [Full Text] [Related]  

  • 20. Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?
    Hammett DC; MacFadyen JC
    Can Fam Physician; 2000 Apr; 46():821-3. PubMed ID: 10790814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.